Genetic testing for von Willebrand disease: The case for

Journal of Thrombosis and Haemostasis

Volumn 8, Issue 1, 2010, Pages 13-16

  Peake, I R ^a   Goodeve, A C ^b  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b SHEFFIELD CHILDREN'S NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; DESMOPRESSIN; DNA; GLOBIN; GLYCOPROTEIN IB ALPHA; VON WILLEBRAND FACTOR;

ARTICLE; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DNA DETERMINATION; ENVIRONMENTAL FACTOR; GENE IDENTIFICATION; GENE MUTATION; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HEALTH CARE COST; HEMOPHILIA A; HEREDITY; HUMAN; MOLECULAR CLONING; PATIENT REFERRAL; PHENOTYPE; PRENATAL DIAGNOSIS; PRIORITY JOURNAL; TREATMENT OUTCOME; VON WILLEBRAND DISEASE;

COST-BENEFIT ANALYSIS; DNA MUTATIONAL ANALYSIS; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HUMANS; MUTATION; PHENOTYPE; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; VON WILLEBRAND DISEASES; VON WILLEBRAND FACTOR;

EID: 73049096908     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2009.03670.x     Document Type: Article

References (17)

1. Sadler JE, Budde U, Eikenboom JC, Favaloro EJ, Hill FG, Holmberg L, Ingerslev J, Lee CA, Lillicrap D, Mannucci PM, Mazurier C, Meyer D, Nichols WL, Nishino M, Peake IR, Rodeghiero F, Schneppenheim R, Ruggeri ZM, Srivastava A, Montgomery RR. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost 2006, 4:2103-14.
2. http://www.vwf.group.shef.ac.uk, International Society on Thrombosis and Haemostasis Scientific and Standardization Committee on VWF Information Homepage. August 2009
3. Lavery S. Preimplantation genetic diagnosis of haemophilia. Br J Haematol 2009, 144:303-7.
4. Keeney S, Bowen D, Cumming A, Enayat S, Goodeve A, Hill M. The molecular analysis of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors' Organisation Haemophilia Genetics Laboratory Network. Haemophilia 2008, 14:1099-111.
5. Goodeve AC, James P. von Willebrand disease. http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&part=von-willebrand, Available on NCBI Gene Reviews. August 2009
6. Goodeve AC, Al-Baba S, Panayi M. Mutations leading to reduced von Willebrand factor binding to factor VIII are uncommon among patients referred for type 2N von Willebrand disease genetic analysis. Platelets 2009, 20(S1):S14 O6.
7. Nichols WL, Hultin MB, James AH, Manco-Johnson MJ, Montgomery RR, Ortel TL, Rick ME, Sadler JE, Weinstein M, Yawn BP. von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia 2008, 14:171-232.
8. Caron C, Fressinaud E, Ternisien C, Wolf M, Veyradier A, Goudemand J. An accurate and routinely adapted enzyme-linked immunosorbent assay for type 2N von Willebrand disease diagnosis. J Thromb Haemost 2009, 7(Suppl. 2):1-1268. PP-MO-626
9. Othman M. Platelet type von Willebrand disease homepage. http://www.pt-vwd.org, August 2009
10. Federici AB, Mannucci PM, Castaman G, Baronciani L, Bucciarelli P, Canciani MT, Pecci A, Lenting PJ, De Groot PG. Clinical and molecular predictors of thrombocytopenia and risk of bleeding in patients with von Willebrand disease type 2B: a cohort study of 67 patients. Blood 2009, 113:526-34.
11. Cumming A, Grundy P, Keeney S, Lester W, Enayat S, Guilliatt A, Bowen D, Pasi J, Keeling D, Hill F, Bolton-Maggs PH, Hay C, Collins P. An investigation of the von Willebrand factor genotype in UK patients diagnosed to have type 1 von Willebrand disease. Thromb Haemost 2006, 96:630-41.
12. Goodeve A, Eikenboom J, Castaman G, Rodeghiero F, Federici AB, Batlle J, Meyer D, Mazurier C, Goudemand J, Schneppenheim R, Budde U, Ingerslev J, Habart D, Vorlova Z, Holmberg L, Lethagen S, Pasi J, Hill F, Hashemi Soteh M, Baronciani L. Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD). Blood 2007, 109:112-21.
13. James PD, Notley C, Hegadorn C, Leggo J, Tuttle A, Tinlin S, Brown C, Andrews C, Labelle A, Chirinian Y, O'Brien L, Othman M, Rivard G, Rapson D, Hough C, Lillicrap D. The mutational spectrum of type 1 von Willebrand disease: Results from a Canadian cohort study. Blood 2007, 109:145-54.
14. Budde U, Schneppenheim R, Eikenboom J, Goodeve A, Will K, Drewke E, Castaman G, Rodeghiero F, Federici AB, Batlle J, Perez A, Meyer D, Mazurier C, Goudemand J, Ingerslev J, Habart D, Vorlova Z, Holmberg L, Lethagen S, Pasi J. Detailed von Willebrand factor multimer analysis in patients with von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease (MCMDM-1VWD). J Thromb Haemost 2008, 6:762-71.
15. James P, Hegadorn C, Grabell J, Ong E, Rapson D, Canada AoHCDo, Budde U, Lillicrap D. Comparative analysis of von Willebrand factor multimers from the Canadian type 1 VWD study. J Thromb Haemost 2009, 7(Suppl. 2):1-1268. PP-TH-639
16. Haberichter SL, Castaman G, Budde U, Peake I, Goodeve A, Rodeghiero F, Federici AB, Batlle J, Meyer D, Mazurier C, Goudemand J, Eikenboom J, Schneppenheim R, Ingerslev J, Vorlova Z, Habart D, Holmberg L, Lethagen S, Pasi J, Hill FG. Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: molecular and clinical markers for the diagnosis and management of type 1 VWD (MCMDM-1VWD). Blood 2008, 111:4979-85.
17. Lenting PJ, Westein E, Terraube V, Ribba AS, Huizinga EG, Meyer D, de Groot PG, Denis CV. An experimental model to study the in vivo survival of von Willebrand factor. Basic aspects and application to the R1205H mutation. J Biol Chem 2004, 279:12102-9.